Pomerantz Law Firm Investigates Sarepta Therapeutics After Investor Claims Arise

Investigation into Sarepta Therapeutics by Pomerantz LLP

Pomerantz LLP, a prominent law firm known for its specialized focus on corporate and securities class litigation, has announced an investigation into Sarepta Therapeutics, Inc. This inquiry follows significant allegations concerning potential unlawful business practices within the company, specifically involving its management team.

The catalyst for this investigation emerged after a tragic incident was reported on March 18, 2025. Sarepta disclosed the unfortunate death of a young man suffering from Duchenne muscular dystrophy, which occurred after he was treated with the company's drug ELEVIDYS. It was revealed that the patient experienced acute liver failure post-treatment. Following this alarming announcement, Sarepta’s stock price plummeted by $27.81 per share, translating to a remarkable 27.44% decrease, closing the day at $73.54.

Given the severity of the allegations and the significant impact on investor confidence, Pomerantz is reaching out to affected Sarepta investors to assess their legal options. The firm's investigation centers around whether Sarepta and its officers or directors have engaged in fraudulent activities that could violate securities laws. Investors who believe they may have been harmed are urged to contact Pomerantz for further information on potential class action participation.

Pomerantz LLP has a long and distinguished history in this area, having been established over 85 years ago by Abraham L. Pomerantz, often referred to as the dean of the class action bar. The firm has been at the forefront of advocating for the rights of investors, recovering millions in damages through various class action lawsuits. This tradition of fighting against corporate misconduct continues to this day as they seek to hold those responsible accountable.

As the investigation progresses, it will be crucial for investors to stay informed regarding any developments that may arise. Given the circumstances surrounding Sarepta’s recent disclosures, this may be an opportune time for affected stakeholders to consider their legal positions promptly. Pomerantz encourages any investor with information or concerns to reach out directly to the firm.

In conclusion, the situation underscores the importance of corporate governance and accountability in the biotechnology sector, particularly as companies navigate the regulatory landscape and manage their public obligations to investors. As Pomerantz pursues clarity and justice for those impacted, it highlights the broader implications for market confidence in the therapeutic industry. For updates and more information on how to proceed if affected, investors are encouraged to visit Pomerantz's official website or contact their offices directly.

Contact Information

If you are an investor and wish to learn more about the ongoing investigation, please contact Danielle Peyton at Pomerantz LLP at danielle.peyton@pomlaw.com or call 646-581-9980, ext. 7980.